应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
RIGL Rigel Pharmaceuticals
交易中 11-03 11:35:00 EST
50.03
-0.50
-1.00%
最高
51.29
最低
50.03
成交量
8.24万
今开
50.44
昨收
50.53
日振幅
2.50%
总市值
9.34亿
流通市值
7.43亿
总股本
1,868万
成交额
416.77万
换手率
0.56%
流通股本
1,485万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Rigel宣布Veppanu™(Vepdegestrant)正式上市,用于ER+/HER2-、ESR1突变型晚期或转移性乳腺癌患者
美股速递 · 08-13
Rigel宣布Veppanu™(Vepdegestrant)正式上市,用于ER+/HER2-、ESR1突变型晚期或转移性乳腺癌患者
Rigel Pharmaceuticals任命Alison L. Hannah为执行副总裁兼首席医疗官,2026年7月1日生效
美股速递 · 07-02
Rigel Pharmaceuticals任命Alison L. Hannah为执行副总裁兼首席医疗官,2026年7月1日生效
Arvinas与辉瑞携手Rigel Pharmaceuticals,就Veppanu(Vepdegestrant)达成全球独家授权交易
美股速递 · 05-12
Arvinas与辉瑞携手Rigel Pharmaceuticals,就Veppanu(Vepdegestrant)达成全球独家授权交易
Rigel Pharmaceuticals 就口服PROTAC药物Veppanu™达成独家全球许可协议,用于治疗2L+ ER+/HER2-、ESR1突变晚期或转移性乳腺癌
美股速递 · 05-12
Rigel Pharmaceuticals 就口服PROTAC药物Veppanu™达成独家全球许可协议,用于治疗2L+ ER+/HER2-、ESR1突变晚期或转移性乳腺癌
Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.75%报19.34美元
市场透视 · 2025-03-10
Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.75%报19.34美元
花旗:维持Rigel Pharmaceuticals(RIGL.US)评级,由买入调整至买入评级, 目标价由49.00美元调整至55.00美元。
金融界 · 2025-03-06
花旗:维持Rigel Pharmaceuticals(RIGL.US)评级,由买入调整至买入评级, 目标价由49.00美元调整至55.00美元。
Rigel Pharmaceuticals, Inc.盘中异动 早盘快速下挫8.49%
市场透视 · 2025-03-05
Rigel Pharmaceuticals, Inc.盘中异动 早盘快速下挫8.49%
Rigel Pharmaceuticals(RIGL.US):2024年Q4财报实现营收5759.6万美元,前值为3579.2万美元,预期值为5759万美元;每股收益为0.80美元,前值为0.04美元,预期值为0.55美元。
金融界 · 2025-03-05
Rigel Pharmaceuticals(RIGL.US):2024年Q4财报实现营收5759.6万美元,前值为3579.2万美元,预期值为5759万美元;每股收益为0.80美元,前值为0.04美元,预期值为0.55美元。
Rigel Pharmaceuticals第四季度每股收益$0.80,超出预期$0.47,销售额$57.60M,超出预期$51.73M
财报速递 · 2025-03-05
Rigel Pharmaceuticals第四季度每股收益$0.80,超出预期$0.47,销售额$57.60M,超出预期$51.73M
Rigel Pharmaceuticals, Inc.盘中异动 大幅上涨5.19%
市场透视 · 2025-02-27
Rigel Pharmaceuticals, Inc.盘中异动 大幅上涨5.19%
Rigel Pharmaceuticals, Inc.盘中异动 大幅上涨5.53%报21.20美元
市场透视 · 2025-02-24
Rigel Pharmaceuticals, Inc.盘中异动 大幅上涨5.53%报21.20美元
Rigel Pharmaceuticals, Inc.盘中异动 临近午盘大幅下挫5.13%报20.36美元
市场透视 · 2025-02-12
Rigel Pharmaceuticals, Inc.盘中异动 临近午盘大幅下挫5.13%报20.36美元
Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.26%报20.79美元
市场透视 · 2025-02-10
Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.26%报20.79美元
Rigel Pharmaceuticals, Inc.盘中异动 股价大涨5.04%报23.99美元
市场透视 · 2025-02-07
Rigel Pharmaceuticals, Inc.盘中异动 股价大涨5.04%报23.99美元
Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.11%报21.93美元
市场透视 · 2025-02-06
Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.11%报21.93美元
Rigel Pharmaceuticals, Inc.盘中异动 股价大跌5.08%
市场透视 · 2025-02-03
Rigel Pharmaceuticals, Inc.盘中异动 股价大跌5.08%
Rigel Pharmaceuticals, Inc.盘中异动 下午盘急速跳水5.62%报21.33美元
市场透视 · 2025-02-01
Rigel Pharmaceuticals, Inc.盘中异动 下午盘急速跳水5.62%报21.33美元
Rigel Pharmaceuticals, Inc.盘中异动 早盘大幅上涨5.13%
市场透视 · 2025-01-17
Rigel Pharmaceuticals, Inc.盘中异动 早盘大幅上涨5.13%
Rigel Pharmaceuticals, Inc.盘中异动 股价大涨5.57%
市场透视 · 2025-01-15
Rigel Pharmaceuticals, Inc.盘中异动 股价大涨5.57%
加载更多
公司概况
公司名称:
Rigel Pharmaceuticals
所属市场:
NASDAQ
上市日期:
--
主营业务:
Rigel Pharmaceuticals, Inc.于1996年6月14日成立于特拉华州。该公司是一家生物技术公司,致力于发现、开发和提供新疗法,显著改善血液系统疾病和癌症患者的生活。公司首个获FDA批准的产品是TAVALISSE(六水二钠福司他马替尼)片,这是唯一获批的口服脾脏酪氨酸激酶(SYK)抑制剂,用于治疗对先前治疗反应不足的慢性免疫性血小板减少症(ITP)成人患者。该公司第二个获得FDA批准的产品是REZLIDHIA(olutasidenib)胶囊,用于治疗经FDA批准的试验检测出具有易感异柠檬酸脱氢酶-1(IDH1)突变的复发或难治性(R/R)急性髓系白血病(AML)成人患者。
发行价格:
--
{"stockData":{"symbol":"RIGL","market":"US","secType":"STK","nameCN":"Rigel Pharmaceuticals","latestPrice":50.025,"timestamp":1793723656440,"preClose":50.53,"halted":0,"volume":82444,"delay":0,"changeRate":-0.009994062932911192,"floatShares":14846600,"shares":18679864,"eps":16.450558,"marketStatus":"交易中","change":-0.505,"latestTime":"11-03 11:35:00 EST","open":50.44,"high":51.2875,"low":50.025,"amount":4167736.29452,"amplitude":0.024985,"askPrice":50.08,"askSize":227,"bidPrice":49.94,"bidSize":70,"shortable":3,"etf":0,"ttmEps":16.450558,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1793739600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":975474000000,"exchange":"NASDAQ","adjPreClose":50.53,"preHourTrading":{"tag":"盘前","latestPrice":52,"preClose":50.53,"latestTime":"09:14 EST","volume":100,"amount":5200,"timestamp":1793715252433,"change":1.47,"changeRate":0.029092,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":50.53,"preClose":50.53,"latestTime":"19:30 EST","volume":2842,"amount":143604.76,"timestamp":1793665801978,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.538279,"impliedVol":0.6719,"impliedVolPercentile":0.4741},"requestUrl":"/m/hq/s/RIGL","defaultTab":"news","newsList":[{"id":"1147653562","title":"Rigel宣布Veppanu™(Vepdegestrant)正式上市,用于ER+/HER2-、ESR1突变型晚期或转移性乳腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1147653562","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147653562?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:07","pubTimestamp":1786622856,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals正式宣布,其自主研发的Veppanu™(Vepdegestrant)现已全面上市。这款靶向治疗药物,专门针对ER阳性、HER2阴性且携带ESR1基因突变的晚期或转移性乳腺癌患者。该消息一经发布,便迅速在肿瘤治疗领域引发广泛关注。对于此前内分泌治疗无果或进展的患者而言,这一新药或将带来全新的治疗选择。Rigel通过精准的研发路径,将药物迅速推向临床,意在填补当前治疗领域中的关键空白。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136500156","title":"Rigel Pharmaceuticals任命Alison L. Hannah为执行副总裁兼首席医疗官,2026年7月1日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1136500156","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136500156?lang=zh_cn&edition=full","pubTime":"2026-07-02 04:14","pubTimestamp":1782936870,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals宣布了一项重要的人事任命。Alison L. Hannah女士将于2026年7月1日正式加入公司,担任执行副总裁兼首席医疗官。作为新任首席医疗官,Hannah女士将负责领导公司的全球临床开发、药政事务及医疗事务团队。这一任命旨在加强Rigel在关键治疗领域的临床开发战略和执行能力。Rigel Pharmaceuticals致力于发现、开发并为患者提供新型小分子药物,其研发重点集中于血液学、肿瘤学及免疫学相关疾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157887878","title":"Arvinas与辉瑞携手Rigel Pharmaceuticals,就Veppanu(Vepdegestrant)达成全球独家授权交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1157887878","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157887878?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:01","pubTimestamp":1778583714,"startTime":"0","endTime":"0","summary":"Arvinas Holding Company LLC与辉瑞公司已同Rigel Pharmaceuticals达成一项协议,获得其药物Veppanu(Vepdegestrant)的全球独家权利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4599","PFE","IE0002270589.USD","BK4534","SG9999011175.SGD","BK4007","BK4581","LU0225284248.USD","IE00BLSP4239.USD","LU1066053197.SGD","LU0456855351.SGD","ARVN","IE00B19Z3581.USD","BK4588","LU0225771236.USD","LU1066051498.USD","IE00BBT3K403.USD","SG9999002224.SGD","LU0306806265.USD","RIGL","IE00B19Z3B42.SGD","LU0306807586.USD","SGXZ57979304.SGD","LU1894683264.USD","BK4533","LU0321505868.SGD","SG9999013999.USD","LU0985481810.HKD","SG9999001176.SGD","BK4568","LU1883839398.USD","LU0234572021.USD","LU0170899867.USD","LU0122379950.USD","LU1894683348.USD","IE00BLSP4452.SGD","BK4550","SG9999003800.SGD","SG9999001176.USD","IE00B3T34201.USD","LU1057294990.SGD","LU0058720904.USD","BK4592","SG9999002232.USD","LU0868494617.USD","IE000M9KFDE8.USD","LU0289739699.SGD","LU1023059063.AUD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139312148","title":"Rigel Pharmaceuticals 就口服PROTAC药物Veppanu™达成独家全球许可协议,用于治疗2L+ ER+/HER2-、ESR1突变晚期或转移性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1139312148","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139312148?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:01","pubTimestamp":1778583687,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals 已就口服PROTAC药物Veppanu™(通用名:Vepdegestrant)达成了一项独家全球许可协议。该药物旨在用于治疗二线及以后(2L+)的雌激素受体阳性/人表皮生长因子受体2阴性(ER+/HER2-)、且携带雌激素受体1(ESR1)突变的晚期或转移性乳腺癌患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518614275","title":"Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.75%报19.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518614275","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518614275?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:54","pubTimestamp":1741614856,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时54分,Rigel Pharmaceuticals, Inc.股票出现波动,股价急速下挫5.75%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.21%。其相关个股中,Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大,Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃,换手率分别为2864.76%、638.63%、141.33%,振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.,振幅分别为40.24%、28.59%、25.35%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021541798a2a2f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021541798a2a2f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517421161","title":"花旗:维持Rigel Pharmaceuticals(RIGL.US)评级,由买入调整至买入评级, 目标价由49.00美元调整至55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517421161","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517421161?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:22","pubTimestamp":1741274556,"startTime":"0","endTime":"0","summary":"花旗:维持Rigel Pharmaceuticals(RIGL.US)评级,由买入调整至买入评级, 目标价由49.00美元调整至55.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06232248576365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517948320","title":"Rigel Pharmaceuticals, Inc.盘中异动 早盘快速下挫8.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517948320?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:31","pubTimestamp":1741185079,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时31分,Rigel Pharmaceuticals, Inc.股票出现波动,股价快速下挫8.49%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.08%。其相关个股中,Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大,Silexion Therapeutics Corp、Tc Biopharm Plc、Zyversa Therapeutics, Inc.较为活跃,换手率分别为318.54%、251.99%、184.79%,振幅较大的相关个股有Aditxt, Inc.、天境生物、Dianthus Therapeutics, Inc.,振幅分别为23.90%、11.10%、9.87%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223119a260c717&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223119a260c717&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517983989","title":"Rigel Pharmaceuticals(RIGL.US):2024年Q4财报实现营收5759.6万美元,前值为3579.2万美元,预期值为5759万美元;每股收益为0.80美元,前值为0.04美元,预期值为0.55美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517983989","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517983989?lang=zh_cn&edition=full","pubTime":"2025-03-05 05:11","pubTimestamp":1741122692,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals(RIGL.US):2024年Q4财报实现营收5759.6万美元,前值为3579.2万美元,预期值为5759万美元;每股收益为0.80美元,前值为0.04美元,预期值为0.55美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05051148524473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155217362","title":"Rigel Pharmaceuticals第四季度每股收益$0.80,超出预期$0.47,销售额$57.60M,超出预期$51.73M","url":"https://stock-news.laohu8.com/highlight/detail?id=1155217362","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155217362?lang=zh_cn&edition=full","pubTime":"2025-03-05 05:10","pubTimestamp":1741122639,"startTime":"0","endTime":"0","summary":"Rigel Pharmaceuticals 报告季度每股收益为$0.80,高出分析师预期的$0.47,超出幅度为70.21%。这是较去年同期每股收益$0.04增长了1900%。以上内容来自Benzinga Earnings专栏,原文如下:$Rigel Pharmaceuticals$ reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.47 by 70.21 percent. This is a 1900 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $57.60 million which beat the analyst consensus estimate of $51.73 million by 11.34 percent. This is ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Rigel Pharmaceuticals第四季度每股收益$0.80,超出预期$0.47,销售额$57.60M,超出预期$51.73M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514085743","title":"Rigel Pharmaceuticals, Inc.盘中异动 大幅上涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514085743","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514085743?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:08","pubTimestamp":1740586113,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日00时08分,Rigel Pharmaceuticals, Inc.股票出现波动,股价快速拉升5.19%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.25%。其相关个股中,Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大,Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃,换手率分别为5651.73%、210.39%、202.73%,振幅较大的相关个股有Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ,振幅分别为161.02%、43.31%、41.71%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227000833a2550da8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227000833a2550da8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513727364","title":"Rigel Pharmaceuticals, Inc.盘中异动 大幅上涨5.53%报21.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513727364","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513727364?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:38","pubTimestamp":1740407923,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时38分,Rigel Pharmaceuticals, Inc.股票出现波动,股价急速拉升5.53%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.21%。其相关个股中,Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大,Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃,换手率分别为55.26%、47.30%、24.53%,振幅较大的相关个股有Pepgen Inc.、Vaxart, Inc. - Common Stock、Gossamer Bio, Inc.,振幅分别为92.70%、21.42%、14.69%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242238449890f78c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502242238449890f78c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510332937","title":"Rigel Pharmaceuticals, Inc.盘中异动 临近午盘大幅下挫5.13%报20.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510332937","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510332937?lang=zh_cn&edition=full","pubTime":"2025-02-12 01:00","pubTimestamp":1739293214,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日01时00分,Rigel Pharmaceuticals, Inc.股票出现异动,股价急速跳水5.13%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为1.55%。其相关个股中,Omega Therapeutics, Inc.、Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.涨幅较大,Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃,换手率分别为3007.57%、1338.48%、438.53%,振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.,振幅分别为143.33%、59.46%、58.60%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212010014961f612e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212010014961f612e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510653928","title":"Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.26%报20.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510653928","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510653928?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:44","pubTimestamp":1739198644,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时44分,Rigel Pharmaceuticals, Inc.股票出现波动,股价急速下挫5.26%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.08%。其相关个股中,Biodexa Pharmaceuticals Plc、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大,Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃,换手率分别为2016.42%、1139.65%、727.94%,振幅较大的相关个股有Biodexa Pharmaceuticals Plc、Ocean Biomedical, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029,振幅分别为53.32%、39.80%、39.13%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021022440498807ad0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021022440498807ad0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509201406","title":"Rigel Pharmaceuticals, Inc.盘中异动 股价大涨5.04%报23.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509201406","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509201406?lang=zh_cn&edition=full","pubTime":"2025-02-07 00:53","pubTimestamp":1738860783,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日00时53分,Rigel Pharmaceuticals, Inc.股票出现异动,股价大幅拉升5.04%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.01%。其相关个股中,Lipella Pharmaceuticals Inc.、Geovax Labs Inc C/Wts 29/09/2025、Palatin Technologies, Inc.涨幅较大,Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc较为活跃,换手率分别为5904.30%、1567.01%、158.59%,振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Palatin Technologies, Inc.,振幅分别为125.58%、53.02%、49.54%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207005303987ca487&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207005303987ca487&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509235876","title":"Rigel Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.11%报21.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509235876","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509235876?lang=zh_cn&edition=full","pubTime":"2025-02-06 00:01","pubTimestamp":1738771303,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日00时01分,Rigel Pharmaceuticals, Inc.股票出现波动,股价急速上涨5.11%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.29%。其相关个股中,Transcode Therapeutics, Inc.、Oragenics Inc.、Pasithea Therapeutics Corp.涨幅较大,Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃,换手率分别为4203.78%、1492.21%、1274.54%,振幅较大的相关个股有Transcode Therapeutics, Inc.、Oragenics Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028,振幅分别为96.10%、59.80%、54.05%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206000143987b8c4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206000143987b8c4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508149798","title":"Rigel Pharmaceuticals, Inc.盘中异动 股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508149798","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508149798?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:31","pubTimestamp":1738593115,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时31分,Rigel Pharmaceuticals, Inc.股票出现异动,股价快速下挫5.08%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.29%。其相关个股中,Hcw Biologics Inc.、Gh Research Plc、Briacell Therapeutics Corp.涨幅较大,Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃,换手率分别为313.51%、209.90%、126.36%,振幅较大的相关个股有Hcw Biologics Inc.、Briacell Therapeutics Corp.、Tc Biopharm Plc,振幅分别为14.02%、11.95%、11.75%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223155a2380944&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223155a2380944&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508999368","title":"Rigel Pharmaceuticals, Inc.盘中异动 下午盘急速跳水5.62%报21.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508999368","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508999368?lang=zh_cn&edition=full","pubTime":"2025-02-01 02:59","pubTimestamp":1738349974,"startTime":"0","endTime":"0","summary":"北京时间2025年02月01日02时59分,Rigel Pharmaceuticals, Inc.股票出现异动,股价急速跳水5.62%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.68%。其相关个股中,Nls Pharmaceutics Ltd C/Wts 02/02/2026、Metsera, Inc.、Seastar Medical Holding Corporation涨幅较大,Cyclerion Therapeutics, Inc.、Nls Pharmaceutics Ltd.、Silexion Therapeutics Corp较为活跃,换手率分别为2736.79%、2028.61%、200.07%,振幅较大的相关个股有180 Life Sciences Corp C/Wts 07/11/2025、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Seastar Medical Holding Corporation,振幅分别为121.11%、80.00%、69.36%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201025934a23570e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201025934a23570e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504160402","title":"Rigel Pharmaceuticals, Inc.盘中异动 早盘大幅上涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504160402","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504160402?lang=zh_cn&edition=full","pubTime":"2025-01-17 23:00","pubTimestamp":1737126043,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日23时00分,Rigel Pharmaceuticals, Inc.股票出现波动,股价急速拉升5.13%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.55%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117230043986a1cd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117230043986a1cd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RIGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503164046","title":"Rigel Pharmaceuticals, Inc.盘中异动 股价大涨5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503164046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503164046?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:48","pubTimestamp":1736952494,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时48分,Rigel Pharmaceuticals, Inc.股票出现异动,股价大幅上涨5.57%。Rigel Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.89%。其相关个股中,Dermata Therapeutics Inc C/Wts 、Lexaria Bioscience Corp C/Wts 14/01/2026 、Os Therapies Incorporated涨幅较大,Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Os Therapies Incorporated较为活跃,换手率分别为194.50%、104.75%、66.21%,振幅较大的相关个股有Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Os Therapies Incorporated、Eterna Therapeutics Inc.,振幅分别为50.00%、46.88%、23.73%。Rigel Pharmaceuticals, Inc.公司简介:里格尔制药有限公司开发用于自身免疫性疾病、癌症相关疾病和病毒性疾病的小分子药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115224814a22302bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115224814a22302bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RIGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.rigel.com","stockEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0717},{"period":"3month","weight":0.3057},{"period":"6month","weight":0.8946},{"period":"1year","weight":0.6001},{"period":"ytd","weight":0.1798}],"compareEarnings":[{"period":"1week","weight":-0.0173},{"period":"1month","weight":-0.0228},{"period":"3month","weight":-0.0249},{"period":"6month","weight":0.0249},{"period":"1year","weight":0.1027},{"period":"ytd","weight":0.1029}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Rigel Pharmaceuticals, Inc.于1996年6月14日成立于特拉华州。该公司是一家生物技术公司,致力于发现、开发和提供新疗法,显著改善血液系统疾病和癌症患者的生活。公司首个获FDA批准的产品是TAVALISSE(六水二钠福司他马替尼)片,这是唯一获批的口服脾脏酪氨酸激酶(SYK)抑制剂,用于治疗对先前治疗反应不足的慢性免疫性血小板减少症(ITP)成人患者。该公司第二个获得FDA批准的产品是REZLIDHIA(olutasidenib)胶囊,用于治疗经FDA批准的试验检测出具有易感异柠檬酸脱氢酶-1(IDH1)突变的复发或难治性(R/R)急性髓系白血病(AML)成人患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.384615,"avgChangeRate":-0.021118},{"month":2,"riseRate":0.423077,"avgChangeRate":-0.030269},{"month":3,"riseRate":0.5,"avgChangeRate":0.003676},{"month":4,"riseRate":0.538462,"avgChangeRate":0.029561},{"month":5,"riseRate":0.346154,"avgChangeRate":0.000389},{"month":6,"riseRate":0.423077,"avgChangeRate":0.018481},{"month":7,"riseRate":0.5,"avgChangeRate":-0.001375},{"month":8,"riseRate":0.461538,"avgChangeRate":0.045473},{"month":9,"riseRate":0.5,"avgChangeRate":0.020261},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.05269},{"month":11,"riseRate":0.423077,"avgChangeRate":0.077753},{"month":12,"riseRate":0.461538,"avgChangeRate":0.119534}],"exchange":"NASDAQ","name":"Rigel Pharmaceuticals","nameEN":"Rigel Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Rigel Pharmaceuticals(RIGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Rigel Pharmaceuticals(RIGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Rigel Pharmaceuticals,RIGL,Rigel Pharmaceuticals股票,Rigel Pharmaceuticals股票老虎,Rigel Pharmaceuticals股票老虎国际,Rigel Pharmaceuticals行情,Rigel Pharmaceuticals股票行情,Rigel Pharmaceuticals股价,Rigel Pharmaceuticals股市,Rigel Pharmaceuticals股票价格,Rigel Pharmaceuticals股票交易,Rigel Pharmaceuticals股票购买,Rigel Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Rigel Pharmaceuticals(RIGL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Rigel Pharmaceuticals(RIGL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}